Who are Beriplex® P/N (Kcentra)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Factor Concentrate (Bebulin), Haemocomplettan® P.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/beriplex-p-n-kcentra.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Beriplex® P/N (Kcentra) — Competitive Intelligence Brief

Beriplex® P/N (Kcentra) (Beriplex® P/N (Kcentra)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prothrombin complex concentrate (PCC). Area: Hematology / Anticoagulation reversal.

phase 3 Prothrombin complex concentrate (PCC) Vitamin K-dependent clotting factors (Factors II, VII, IX, X) Hematology / Anticoagulation reversal Biologic Live · refreshed every 30 min

Target snapshot

Beriplex® P/N (Kcentra) (Beriplex® P/N (Kcentra)) — CSL Behring. Beriplex P/N is a prothrombin complex concentrate that replaces deficient vitamin K-dependent clotting factors to rapidly reverse warfarin anticoagulation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Beriplex® P/N (Kcentra) TARGET	Beriplex® P/N (Kcentra)	CSL Behring	phase 3	Prothrombin complex concentrate (PCC)	Vitamin K-dependent clotting factors (Factors II, VII, IX, X)
Factor Concentrate (Bebulin)	Factor Concentrate (Bebulin)	The University of Texas Health Science Center, Houston	marketed	Prothrombin complex concentrate (PCC)	Coagulation factors II, VII, IX, X
Haemocomplettan® P	Haemocomplettan® P	CSL Behring	marketed	Prothrombin complex concentrate (PCC)	Clotting factors II, VII, IX, X

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prothrombin complex concentrate (PCC) class)

CSL Behring · 2 drugs in this class
The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Beriplex® P/N (Kcentra) — Competitive Intelligence Brief. https://druglandscape.com/ci/beriplex-p-n-kcentra. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab